Cargando…

Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study

BACKGROUND: Previous studies have shown mortality benefits with corticosteroids in Coronavirus disease-19 (COVID-19). However, there is inconsistency regarding the use of methylprednisolone over dexamethasone in COVID-19, and this has not been extensively evaluated in patients with a history of asth...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Sulaiman, Khalid, Aljuhani, Ohoud, Korayem, Ghazwa B., Altebainawi, Ali, Alharbi, Reham, Assadoon, Maha, Vishwakarma, Ramesh, Ismail, Nadia H., Alshehri, Asma A., Al Mutairi, Faisal E., AlFaifi, Mashael, Alharthi, Abdullah F., Alenazi, Abeer A., Alalawi, Mai, Al Zumai, Omar, Al Haji, Hussain, Al Dughaish, Sarah T., Alawaji, Abdulrahman S., Alhaidal, Haifa A., Al Ghamdi, Ghassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463591/
https://www.ncbi.nlm.nih.gov/pubmed/37641042
http://dx.doi.org/10.1186/s12890-023-02603-4
_version_ 1785098267154972672
author Al Sulaiman, Khalid
Aljuhani, Ohoud
Korayem, Ghazwa B.
Altebainawi, Ali
Alharbi, Reham
Assadoon, Maha
Vishwakarma, Ramesh
Ismail, Nadia H.
Alshehri, Asma A.
Al Mutairi, Faisal E.
AlFaifi, Mashael
Alharthi, Abdullah F.
Alenazi, Abeer A.
Alalawi, Mai
Al Zumai, Omar
Al Haji, Hussain
Al Dughaish, Sarah T.
Alawaji, Abdulrahman S.
Alhaidal, Haifa A.
Al Ghamdi, Ghassan
author_facet Al Sulaiman, Khalid
Aljuhani, Ohoud
Korayem, Ghazwa B.
Altebainawi, Ali
Alharbi, Reham
Assadoon, Maha
Vishwakarma, Ramesh
Ismail, Nadia H.
Alshehri, Asma A.
Al Mutairi, Faisal E.
AlFaifi, Mashael
Alharthi, Abdullah F.
Alenazi, Abeer A.
Alalawi, Mai
Al Zumai, Omar
Al Haji, Hussain
Al Dughaish, Sarah T.
Alawaji, Abdulrahman S.
Alhaidal, Haifa A.
Al Ghamdi, Ghassan
author_sort Al Sulaiman, Khalid
collection PubMed
description BACKGROUND: Previous studies have shown mortality benefits with corticosteroids in Coronavirus disease-19 (COVID-19). However, there is inconsistency regarding the use of methylprednisolone over dexamethasone in COVID-19, and this has not been extensively evaluated in patients with a history of asthma. This study aims to investigate and compare the effectiveness and safety of methylprednisolone and dexamethasone in critically ill patients with asthma and COVID-19. METHODS: The primary endpoint was the in-hospital mortality. Other endpoints include 30-day mortality, respiratory failure requiring mechanical ventilation (MV), acute kidney injury (AKI), acute liver injury, length of stay (LOS), ventilator-free days (VFDs), and hospital-acquired infections. Propensity score (PS) matching, and regression analyses were used. RESULTS: A total of one hundred-five patients were included. Thirty patients received methylprednisolone, whereas seventy-five patients received dexamethasone. After PS matching (1:1 ratio), patients who received methylprednisolone had higher but insignificant in-hospital mortality in both crude and logistic regression analysis, [(35.0% vs. 18.2%, P = 0.22) and (OR 2.31; CI: 0.56 – 9.59; P = 0.25), respectively]. There were no statistically significant differences in the 30-day mortality, respiratory failure requiring MV, AKI, acute liver injury, ICU LOS, hospital LOS, and hospital-acquired infections. CONCLUSIONS: Methylprednisolone in COVID-19 patients with asthma may lead to increased in-hospital mortality and shorter VFDs compared to dexamethasone; however, it failed to reach statistical significance. Therefore, it is necessary to interpret these data cautiously, and further large-scale randomized clinical trials are needed to establish more conclusive evidence and support these conclusions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-023-02603-4.
format Online
Article
Text
id pubmed-10463591
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104635912023-08-30 Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study Al Sulaiman, Khalid Aljuhani, Ohoud Korayem, Ghazwa B. Altebainawi, Ali Alharbi, Reham Assadoon, Maha Vishwakarma, Ramesh Ismail, Nadia H. Alshehri, Asma A. Al Mutairi, Faisal E. AlFaifi, Mashael Alharthi, Abdullah F. Alenazi, Abeer A. Alalawi, Mai Al Zumai, Omar Al Haji, Hussain Al Dughaish, Sarah T. Alawaji, Abdulrahman S. Alhaidal, Haifa A. Al Ghamdi, Ghassan BMC Pulm Med Research BACKGROUND: Previous studies have shown mortality benefits with corticosteroids in Coronavirus disease-19 (COVID-19). However, there is inconsistency regarding the use of methylprednisolone over dexamethasone in COVID-19, and this has not been extensively evaluated in patients with a history of asthma. This study aims to investigate and compare the effectiveness and safety of methylprednisolone and dexamethasone in critically ill patients with asthma and COVID-19. METHODS: The primary endpoint was the in-hospital mortality. Other endpoints include 30-day mortality, respiratory failure requiring mechanical ventilation (MV), acute kidney injury (AKI), acute liver injury, length of stay (LOS), ventilator-free days (VFDs), and hospital-acquired infections. Propensity score (PS) matching, and regression analyses were used. RESULTS: A total of one hundred-five patients were included. Thirty patients received methylprednisolone, whereas seventy-five patients received dexamethasone. After PS matching (1:1 ratio), patients who received methylprednisolone had higher but insignificant in-hospital mortality in both crude and logistic regression analysis, [(35.0% vs. 18.2%, P = 0.22) and (OR 2.31; CI: 0.56 – 9.59; P = 0.25), respectively]. There were no statistically significant differences in the 30-day mortality, respiratory failure requiring MV, AKI, acute liver injury, ICU LOS, hospital LOS, and hospital-acquired infections. CONCLUSIONS: Methylprednisolone in COVID-19 patients with asthma may lead to increased in-hospital mortality and shorter VFDs compared to dexamethasone; however, it failed to reach statistical significance. Therefore, it is necessary to interpret these data cautiously, and further large-scale randomized clinical trials are needed to establish more conclusive evidence and support these conclusions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-023-02603-4. BioMed Central 2023-08-28 /pmc/articles/PMC10463591/ /pubmed/37641042 http://dx.doi.org/10.1186/s12890-023-02603-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Al Sulaiman, Khalid
Aljuhani, Ohoud
Korayem, Ghazwa B.
Altebainawi, Ali
Alharbi, Reham
Assadoon, Maha
Vishwakarma, Ramesh
Ismail, Nadia H.
Alshehri, Asma A.
Al Mutairi, Faisal E.
AlFaifi, Mashael
Alharthi, Abdullah F.
Alenazi, Abeer A.
Alalawi, Mai
Al Zumai, Omar
Al Haji, Hussain
Al Dughaish, Sarah T.
Alawaji, Abdulrahman S.
Alhaidal, Haifa A.
Al Ghamdi, Ghassan
Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study
title Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study
title_full Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study
title_fullStr Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study
title_full_unstemmed Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study
title_short Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study
title_sort evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with covid-19: a multicenter cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463591/
https://www.ncbi.nlm.nih.gov/pubmed/37641042
http://dx.doi.org/10.1186/s12890-023-02603-4
work_keys_str_mv AT alsulaimankhalid evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT aljuhaniohoud evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT korayemghazwab evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT altebainawiali evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT alharbireham evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT assadoonmaha evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT vishwakarmaramesh evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT ismailnadiah evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT alshehriasmaa evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT almutairifaisale evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT alfaifimashael evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT alharthiabdullahf evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT alenaziabeera evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT alalawimai evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT alzumaiomar evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT alhajihussain evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT aldughaishsaraht evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT alawajiabdulrahmans evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT alhaidalhaifaa evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy
AT alghamdighassan evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy